The correlation of CCR8 with immune checkpoint proteins and genomic instability markers such as TMB and MSI further supports its potential in combination therapies for various cancer types, particularly breast invasive carcinoma (BRCA). This evidence concerns the gene CCR8 and invasive breast carcinoma.